Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

A Phase 3 win against the standard of care sent the biotech’s shares up 131% and left short sellers down $4.8 billion.

Leave a Comment

Your email address will not be published. Required fields are marked *

Chatbot Avatar
Chatbot Avatar
Chat with us! AI assistant
Chatbot Avatar

Hello! How can I help you today?

error: Content is protected !!
Scroll to Top